MedChem

IV delivery neuraminidase inhibitor for susceptible strains of flu available for serious infections by H1N1 via the CDC

Renal toxic drug that selectively inhibits pyrophosphate bonding site of virus-specific DNA polymerase

Inhalation treatment of severe lower respiratory tract infection in pediatric patient infected with respiratory syncytial virus (RSV)

Blocks renal tubular excretion of neuraminidase inhibitors

Treatment of chronic hep B - unmodified beta-L-enatiomer of thymidine

The adamantadine class of drugs are no longer recommended due to complete resistence to these agents

Used in combination with CoPegus and Pegasys - a hep C NS3/4A serine protease inhibitor

Inhalation delivery neuraminidase inhibitor for susceptible strains of flu

Topical for oral/facial Herpes simplex - prodrug that blocks fusion of the virus with the host cellby altering the host cell membrane fluidity

IM monoclonal antibody-prevents protein mediated cell-to-cell fusion of RSV-infected cells by binding to the epitope of the A antigenic site

Primary enzymatic target of phosphorylated nucleoside class antiviral agents which prevents DNA replication and leads to chain termination

Oral delivery neuraminidase inhibitor for susceptible strains of influenza

The most successful approach to date for the prevention of influenza

Used in combo therapy with Pegasys - PEGylated alfa-2a interferon to treat hep C

Topical agent for herpes simplex keratitis of the eye

Prodrug of acyclovir for HSV-1 and -2, shingles, Epstein-Barr mononeucleosis, Varicella

Cleaves sialic acid-glycoproteins; facilitates the spread of newly replicated virus and greatly increases pathogenicity of an influenza strain

Oral use only prodrug of Penciclovir used in acute singles and genital herpes

Only used in cytomegalovirus infections in immune-compromised or transplant patients

Formerly used for flu A - useful in carbon monoxide induced parkinson's 

NNRTI with a black box warning against liver failure and >40% develop Steven-Johnsons syndrome

HIV protease inhibitor that is formulated with Vit E - accordingly do not suppliment with Vit E

NRTI drug also called azidothymidine (AZT) - anemia, neutropenia, and initial therapy = flu-like sx for weeks

Integrase strand inhibitor used in cobo with other agents in resistant HIV strands

Weakest NRTI - not used much today

Approved for prophylactic use to reduce infection rates by HIV

NRTI indicated for pediatric use in patients over 3 mos - not a CYP substrate/no inhibition of glucuronidation

BID SQ injection that interfers with the binding of the GP41 subunits of the viral envelope with the host cell cellular membrane preventing fusion

NRTI with severe HTN that can be determined by pharmacogenomic testing for the HLA-B*5701 gene polymorphism

Azapeptied inhibitor og HIV pretease that is a potent inhibitor of glucuronidation by UGT1A1

Phosphonate nucleotide analogue reverse transcriptase inhibitor with reduced activity against the K65R reverse transcriptase mutation (3% in USA)

Chemokine receptor 5 co-receptor antagonist used only in a CCR5-trophic HIV-1 detectable resistant strain

HIV protease inhibitor with severe diet limitations; no food or low protein/fat food only - must remain hydrated to prevent kidney stones - dispense in factory bottle only

HIV protease inhibitor - rapidly dissolving capsule that must be taken with hight fat food to ensure proper absorption - ie 2 tsp peanut butter

HIV drug use induced lipodystophy treatment

HIV protease inhibitor that must be co-administered with 100mg of ritonavir in order to inhibit CYP3A/2D6 to ensure adequate plasma levels (not Viracept)

NNRTI agent - do not use in combo with any other NNRTI due to increased resistance potential

Prophylactic vaccination against HIV type 16 and 18 that cause cervical cancers

Most poorly tolerated of HIV protease inhibitors - severe diarrhea, flu-like sx, potent CYP 3A/2D6 inhibitor - capssules must be refrigerated

HAART tx results in a severe inflammatory response to opportunistic infective agents present which may need further treatment